机构:[1]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.[3]Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.[4]Jiangsu Mabwell Health Pharmaceutical R&[5]D Co., Ltd., Taizhou, China.
第一作者机构:[1]Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China.[2]Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China.[3]Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
通讯作者:
推荐引用方式(GB/T 7714):
Zhou Wei,Fang Peng,Yu Dongan,et al.Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers[J].Molecular cancer therapeutics.2023,22(8):913-925.doi:10.1158/1535-7163.MCT-22-0743.
APA:
Zhou Wei,Fang Peng,Yu Dongan,Ren Hongyuan,You Meng...&Shen Jingkang.(2023).Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.Molecular cancer therapeutics,22,(8)
MLA:
Zhou Wei,et al."Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers".Molecular cancer therapeutics 22..8(2023):913-925